# A Phase 3 Study With P2B001 in Subjects With Early Parkinson's

> **NCT03329508** · PHASE3 · COMPLETED · sponsor: **Pharma Two B Ltd.** · enrollment: 544 (actual)

## Conditions studied

- Parkinson Disease
- Early Parkinson's Disease

## Interventions

- **DRUG:** P2B001 0.6/0.75 mg
- **DRUG:** Rasagiline 0.75 mg
- **DRUG:** Pramipexole 0.6 mg
- **DRUG:** Marketed Pramipexole ER

## Key facts

- **NCT ID:** NCT03329508
- **Lead sponsor:** Pharma Two B Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-19
- **Primary completion:** 2021-08-23
- **Final completion:** 2021-10-31
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2023-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03329508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03329508, "A Phase 3 Study With P2B001 in Subjects With Early Parkinson's". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03329508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*